| Literature DB >> 35162062 |
Nicolás Francisco Fernández-Martínez1,2, Sheila Cárcel-Fernández2,3,4, Carmen De la Fuente-Martos2,3, Rafael Ruiz-Montero1,2,5, Bernardo R Guzmán-Herrador1, Rafael León-López2,3, Francisco Javier Gómez4, Julia Guzmán-Puche2,6,7, Luis Martínez-Martínez2,6,7,8, Inmaculada Salcedo-Leal1,2,7.
Abstract
Multidrug-resistant Gram-negative bacteria (MDR-GNB) are microorganisms that have acquired resistance to extended-spectrum antibacterials and constitute an emerging threat to public health. Although carriers are an important source of transmission in healthcare settings, data about risk factors for MDR-GNB carriage are limited. Therefore, we aimed to identify risk factors for MDR-GNB carriage upon intensive care unit (ICU) admission and to optimise screening strategies. We conducted a case-control study. Admissions of adult patients to the ICU of a 1000-bed hospital during a year were included. We collected sociodemographic, clinical and microbiological data and performed a multivariate logistic regression model. A total of 1342 patients resulted in 1476 episodes of ICU admission, 91 (6.2%) of whom harboured MDR-GNB (38.5% women; median age 63.9 years). The most frequently isolated pathogens were Escherichia coli (57%) and Klebsiella pneumoniae (16%). The most frequent resistance mechanism was production of extended-spectrum beta lactamases. MDR-GNB carriage was associated to liver cirrhosis (OR 6.54, 95% CI 2.17-19.17), previous MDR-GNB carriage (OR 5.34, 1.55-16.60), digestive surgery (OR 2.83, 1.29-5.89) and length of hospital stay (OR 1.01 per day, 1.00-1.03). Several risk factors for MDR-GNB carriage upon admission to a high-risk setting were identified; the main comorbidity was liver cirrhosis.Entities:
Keywords: antibacterial drug resistance; critical care; epidemiology; gram negative bacteria; infection control; risk factors
Mesh:
Substances:
Year: 2022 PMID: 35162062 PMCID: PMC8834020 DOI: 10.3390/ijerph19031039
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Distribution of the study participants.
Baseline characteristics of cases and controls upon ICU admission.
| Characteristic | Cases | Controls | |
|---|---|---|---|
| Age (years), median (IQR) | 63.87 (52.94, 74.10) | 63.16 (52.60, 73.14) | 0.933 1 |
| Sex | 0.331 2 | ||
| Female | 35 (38.5%) | 456 (32.9%) | |
| Male | 56 (61.5%) | 929 (67.1%) | |
| Stay in congregate settings | 0 | 7 (0.5%) | 1 3 |
| Nursing home | 0 | 4 (0.3%) | |
| Prison | 0 | 2 (0.1%) | |
| Other | 0 | 1 (0.1%) | |
| Referring ward | <0.001 *4 | ||
| Cardiology | 24 (26.4%) | 361 (26.1%) | |
| Cardiovascular surgery | 9 (9.9%) | 283 (20.4%) | |
| General & Digestive surgery | 7 (7.7%) | 35 (2.5%) | |
| Emergency Department | 19 (20.9%) | 394 (28.4%) | |
| Hepatology | 12 (13.2%) | 63 (4.5%) | |
| Pulmonology | 4 (4.4%) | 69 (5.0%) | |
| Other | 16 (17.6%) | 180 (13.0%) | |
| APACHE classification system | 0.119 4 | ||
| Medical | 73 (80.2%) | 977 (70.5%) | |
| Non-emergency surgical | 13 (14.3%) | 261 (18.8%) | |
| Emergency surgical | 5 (5.5%) | 147 (10.6%) | |
| Previous hospital admissions | 44 (48.4%) | 609 (44.0%) | 0.480 2 |
| Previous hospital admissions (number), median (IQR) | 1 (1, 2) | 1 (1, 2) | 0.311 1 |
| Length of hospital stay in the last year (days), median (IQR) | 5 (0, 16.50) | 2 (0, 7) | 0.001 *1 |
| Previous MDR-GNB carriage | 6 (6.6%) | 13 (0.9%) | 0.001 *3 |
| Cancer chemotherapy | 2 (2.2%) | 46 (3.3%) | 0.844 3 |
| Dialysis | 1 (1.1%) | 18 (1.3%) | 1 3 |
| Previous antibacterial therapy | 15 (16.5%) | 57 (4.1%) | <0.001 *3 |
| Previous therapy with third-, fourth- or fifth-generation cephalosporins | 2 (2.2%) | 10 (0.7%) | 0.332 3 |
| Previous therapy with carbapenems | 2 (2.2%) | 6 (0.4%) | 0.165 3 |
| Cystic fibrosis | 0 | 15 (1.1%) | 0.766 3 |
| Bronchiectasis | 1 (1.1%) | 18 (1.3%) | 1 3 |
| COPD | 9 (9.9%) | 109 (7.9%) | 0.625 2 |
| Chronic ulcers | 0 | 0 | - |
| Liver cirrhosis | 8 (8.8%) | 46 (3.3%) | 0.030 *3 |
| Immunodeficiency | 1 (1.1%) | 12 (0.9%) | 1 3 |
| Cancer | 12 (13.2%) | 131 (9.5%) | 0.326 2 |
| Neutropenia | 6 (6.6%) | 35 (2.5%) | 0.073 3 |
| Type 1 diabetes | 2 (2.2%) | 20 (1.4) | 0.796 3 |
| Type 2 diabetes | 21 (23.1%) | 322 (23.2%) | 0.928 2 |
| Pressure ulcers | 1 (1.1%) | 10 (0.7%) | 1 3 |
| Digestive surgery in the last year | 15 (16.5%) | 50 (3.6%) | <0.001 *3 |
| Previous gastrointestinal endoscopy | 11 (12.1%) | 54 (3.9%) | 0.001 *4 |
| Upper | 7 (7.7%) | 26 (1.9%) | |
| Lower | 4 (4.4%) | 29 (2.1%) | |
| APACHE II score (points), mean (SD) | 17.76 (9.57) | 18.41 (7.51) | 0.528 5 |
| Solid organ transplantation | 10 (11.0%) | 123 (8.9%) | 0.623 2 |
| Hematopoietic stem cell transplantation | 0 | 4 (0.3%) | 1 3 |
| Biliary drainage | 1 (1.1%) | 1 (0.1%) | 0.239 3 |
APACHE: Acute Physiology and Chronic Health Evaluation, COPD: chronic obstructive pulmonary disease, IQR: interquartile range, MDR-GNB: multidrug-resistant Gram-negative bacteria, SD: standard deviation. * p-value < 0.05 of Mann–Whitney U test 1, Pearson’s chi-square test 2, Fisher’s exact test 3, ANOVA’s test 4 or Student’s t-test 5, when appropriate.
MDR-GNB identified in screening upon ICU admission.
| MDR-GNB | Mechanism(s) of Resistance |
| % (Same Species) | % (Overall) |
|---|---|---|---|---|
|
| ESBL production | 56 | 96.6 | 55.4 |
| IMP production | 1 | 1.7 | 1.0 | |
| OXA-48 production | 1 | 1.7 | 1.0 | |
|
| ESBL production | 13 | 81.3 | 12.9 |
| IMP production | 1 | 6.3 | 1.0 | |
| KPC production | 1 | 6.3 | 1.0 | |
| OXA-48 production | 1 | 6.3 | 1.0 | |
|
| AmpC derepression | 4 | 80 | 4.0 |
| ESBL production | 1 | 20 | 1.0 | |
|
| ESBL production | 4 | 100 | 4.0 |
|
| AmpC derepression | 7 | 100 | 6.9 |
|
| AmpC derepression | 4 | 66.7 | 4.0 |
| ESBL production | 1 | 16.7 | 1.0 | |
| OXA-48 production | 1 | 16.7 | 1.0 | |
|
| ESBL production | 2 | 66.7 | 2.0 |
| OXA-48 production | 1 | 33.3 | 1.0 | |
|
| Other * | 2 | 100 | 2.0 |
| Total | - | 101 | - | 100 |
ESBL: extended spectrum beta lactamases, MDR-GNB: multidrug-resistant Gram-negative bacteria. * According to international criteria adapted to regional guidelines, as defined previously.
Risk factors for MDR-GNB carriage upon ICU admission.
| Risk Factor | Crude OR | Adjusted OR (95% CI) | |
|---|---|---|---|
| Liver cirrhosis | 2.81 | 6.54 (2.17–19.17) | <0.001 *1 |
| Previous MDR-GNB carriage | 7.45 | 5.34 (1.55–16.60) | 0.005 *1 |
| Digestive surgery in the last year | 5.27 | 2.83 (1.29–5.89) | 0.007 *1 |
| Length of hospital stay in the last year (days) | 1.02 | 1.01 (1.00–1.03) | 0.026 *1 |
| Previous gastrointestinal endoscopy | 3.63 | 1.98 (0.92–4.01) | 0.067 1 |
| APACHE classification system | 0.098 2 | ||
| Emergency surgical (reference) | 1 | 1 | |
| Non-emergency surgical | 1.46 | 4.10 (1.20–16.71) | |
| Medical | 2.20 | 5.17 (1.76–19.04) | |
| Cancer chemotherapy | 0.65 | 0.27 (0.04–1.07) | 0.113 1 |
| Previous antibacterial therapy | 4.60 | 1.89 (0.83–4.05) | 0.114 1 |
| Sex (female) | 1.27 | 1.32 (0.83–2.08) | 0.234 1 |
| Age (years) | 1.00 | 1.00 (0.98–1.01) | 0.833 1 |
APACHE: Acute Physiology and Chronic Health Evaluation, MDR-GNB: multidrug-resistant Gram-negative bacteria, OR: odds ratio. * p-value < 0.05 of Wald’s test 1 or ANOVA’s test 2, when appropriate.
Figure 2ROC (receiver operating characteristic) curve of the logistic regression model.